Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease.
398 United States sites
155 India sites
125 United Kingdom sites
75 Canada sites
75 Italy sites
50 France sites
50 Spain sites
50 Turkey sites
49 Greece sites
25 South Africa sites
4 Switzerland sites
> 18 Years
Phase 2
This is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance.
This study will validate the diagnostic accuracy of a cutaneous hydration sensor.
This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
357 United States sites
55 Canada sites
32 Lebanon sites
12 Years - 65 Years
Phase 2
The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult participants with severe sickle cell disease (SCD).
424 United States sites
75 Canada sites
18 Years - 50 Years
Phase 1/Phase 2
The trial of IV arginine therapy in children with Vaso-occlusive painful episodes (VOE) in sickle cell disease (SCD) is designed to further knowledge on efficacy and safety of the therapy.
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
1007 United States sites
133 United Kingdom sites
95 France sites
95 Spain sites
76 Greece sites
76 Italy sites
57 Canada sites
38 Lebanon sites
38 Germany sites
38 Oman sites
12 Years - 65 Years
Phase 2/Phase 3
African Americans living with chronic health conditions are more likely to experience depression and other mental health disorders than their healthy counterparts, and are more likely to experience severe depression than whites, but less likely to be diagnosed or receive treatment.
This is a phase 1, first-in-human, multi-center, open-label, single dose cohort study to evaluate the safety and tolerability, pharmacokinetics (PK), exploratory pharmacodynamics (PD), and biomarkers of target engagement of CSL889 following single intravenous (IV) doses in subjects with sickle cell disease (SCD).
152 United States sites
110 United Kingdom sites
44 Netherlands sites
18 Years - 60 Years
Phase 1
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.
134 United States sites
78 Belgium sites
78 Brazil sites
78 Turkey sites
52 France sites
52 Italy sites
52 Lebanon sites
26 Colombia sites
26 Oman sites
26 Germany sites
26 Spain sites
> 6 Months Years
Phase 4
